// App-Quantinova.ai

1185 : Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Researchers

Presenter

  • Andrew Davies

Principal Investigators

  • Josh Caddy

  • Katy Mercer

  • Geoff N Saunders

  • Louise Stanton

  • Graham P. Collins

  • Thomas E C Cummin

  • Anna Schuh

  • Kirit M. Ardeshna

  • Andrew McMillan

  • John A. Radford

  • David John Lewis

  • Adam Coleman

  • Gareth Griffiths

  • Cathy Burton

  • Sharon Barrans

  • Peter Johnson

Medical Centers

  • Cancer Research UK Centre, Cancer Sciences Division, University of Southampton, Southampton, United Kingdom

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Department of Clinical Haematology, Oxford University Hospitals, Oxford, United Kingdom

  • Molecular Diagnostic Centre, Department of Oncology,University of Oxford,Oxford,United Kingdom

  • Department of Haematology, University College Hospitals London, London, United Kingdom

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Department of Haematology, Derriford Hospital, Plymouth, United Kingdom

  • Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • ACP-196

  • Prednisolone

  • Vincristine

  • Doxorubicin

  • Rituximab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Single Arm

Phase

  • I

Study Id's

  • NCT01855750

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved